Significant association of Caveolin-1 (CAV1) genotypes with prostate cancer susceptibility in Taiwan

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 745-749

  Wu, Hsi Chin ^a   Chang, Chao Hsiang ^a   Tsou, Yung An ^a   Tsai, Chia Wen ^a,b   Lin, Cheng Chieh ^a   Bau, Da Tian ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Caveolin 1; DNA repair; Prostate cancer; Single nucleotide polymorphism

Indexed keywords

CAVEOLIN 1;

ADULT; ALLELE; ARTICLE; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENE LOCUS; GENE SEQUENCE; GENOTYPE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; QUESTIONNAIRE; TAIWAN;

CASE-CONTROL STUDIES; CAVEOLIN 1; CHROMOSOMES, HUMAN, PAIR 7; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 79953251675     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Brawley OW, Giovannucci E and Kramer BS: Epidemiology of prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology. Vogelzang SP, Shipley WU and Coffey DS (eds.). Philadelphia: Lippincott Williams and Wilkins, pp. 533-544, 2000.
2. Alers JC, Krijtenburg PJ, Rosenberg C, Hop WC, Verkerk AM, Schroder FH, van der Kwast TH, Bosman FT and van Dekken H: Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 77: 437-448, 1997. (Pubitemid 27508615)
3. Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schroder FH and van Dekken H: Identification of genetic markers for prostatic cancer progression. Lab Invest 80: 931-942, 2000. (Pubitemid 30421809)
4. Cui J, Deubler DA, Rohr LR, Zhu XL, Maxwell TM, Changus JE and Brothman AR: Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. Cancer Genet Cytogenet 107: 51-60, 1998. (Pubitemid 28506746)
5. Latil A, Cussenot O, Fournier G, Baron JC and Lidereau R: Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1: 1385-1389, 1995.
6. Nupponen NN, Kakkola L, Koivisto P and Visakorpi T: Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 153: 141-148, 1998. (Pubitemid 28317516)
7. Tobias ES, Hurlstone AF, MacKenzie E, McFarlane R and Black DM: The TES gene at 7q31.1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein. Oncogene 20: 2844-2853, 2001. (Pubitemid 32549841)
8. Zenklusen JC, Conti CJ and Green ED: Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Nat Genet 27: 392-398, 2001. (Pubitemid 32268419)
9. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN and Jenkins RB: Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 55: 4114-4119, 1995.
10. Chene L, Giroud C, Desgrandchamps F, Boccon-Gibod L, Cussenot O, Berthon P and Latil A: Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. Int J Cancer 111: 798-804, 2004. (Pubitemid 39062907)
11. Hatanaka M, Maeda T, Ikemoto T, Mori H, Seya T and Shimizu A: Expression of caveolin-1 in human T-cell leukemia cell lines. Biochem Biophys Res Commun 253: 382-387, 1998. (Pubitemid 29026712)
12. Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16: 1391-1397, 1998. (Pubitemid 28151846)
13. Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM and Schneider U: Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol 158: 833-839, 2001. (Pubitemid 32221776)
14. Bender FC, Reymond MA, Bron C and Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 60: 5870-5878, 2000.
15. Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S and Miotti S: Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene 19: 4754-4763, 2000.
16. Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne M, Ben-Baruch G, Berner A and Reich R: Caveolin-1 expression in advanced-stage ovarian carcinoma - a clinicopathologic study. Gynecol Oncol 81: 166-171, 2001. (Pubitemid 32424155)
17. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J and Couet J: Reduction of caveolin 1 gene expression in lung Carcinoma cell lines. Biochem Biophys Res Commun 255: 580-586, 1999.
18. Glenney JR Jr. and Soppet D: Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci USA 89: 10517-10521, 1992.
19. Li WP, Liu P, Pilcher BK and Anderson RG: Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J Cell Sci 114: 1397-1408, 2001. (Pubitemid 32409475)
20. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J and Thompson TC: Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4: 1062-1064, 1998. (Pubitemid 28417340)
21. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT and Thompson TC: Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873-1880, 1998.
22. Yang G, Truong LD, Wheeler TM and Thompson TC: Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59: 5719-5723, 1999.
23. Bau DT, Mau YC, Ding SL, Wu PE and Shen CY: DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 28: 1726-1730, 2007.
24. Bau DT, Tseng HC, Wang CH, Chiu CF, Hua CH, Wu CN, Liang SY, Wang CL, Tsai CW and Tsai MH: Oral cancer and genetic polymorphism of DNA double-strand break gene Ku70 in Taiwan. Oral Oncol 44: 1047-1051, 2008.
25. Bau DT, Wu HC, Chiu CF, Lin CC, Hsu CM, Wang CL, Wang RF and Tsai FJ: Association of XPD polymorphisms with prostate cancer in Taiwanese patients. Anticancer Res 27: 2893-2896, 2007.
26. Chang CH, Chang CL, Tsai CW, Wu HC, Chiu CF, Wang RF, Liu CS, Lin CC and Bau DT: Significant association of an XRCC4 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res 29: 1777-1782, 2009.
27. Chang CH, Chiu CF, Wang HC, Wu HC, Tsai RY, Tsai CW, Wang RF, Wang CH, Tsou YA and Bau DT: Significant association of ERCC6 single nucleotide polymorphisms with bladder cancer susceptibility in Taiwan. Anticancer Res 29: 5121-5124, 2009.
28. Chang CH, Wang RF, Tsai RY, Wu HC, Wang CH, Tsai CW, Chang CL, Tsou YA, Liu CS and Bau DT: Significant association of XPD codon 312 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan. Anticancer Res 29: 3903-3907, 2009.
29. Liu CJ, Hsia TC, Wang RF, Tsai CW, Chu CC, Hang LW, Wang CH, Lee HZ, Tsai RY and Bau DT: Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients. Anticancer Res 30: 1195-1199, 2010.
30. Wang HC, Liu CS, Chiu CF, Chiang SY, Wang CH, Wang RF, Lin CC, Tsai RY and Bau DT: Significant association of DNA repair gene Ku80 genotypes with breast cancer susceptibility in Taiwan. Anticancer Res 29: 5251-5254, 2009.
31. Conde MC, Ramirez-Lorca R, Lopez-Jamar JM, Molero E, Ramirez-Armengol JA, Moreno Nogueira JA, Pascual MH, Ruiz A, Martin-Cordova CG, Real LM and Royo JL: Genetic analysis of caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep 16: 353-359, 2006.
32. Han SE, Park KH, Lee G, Huh YJ and Min BM: Mutation and aberrant expression of caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. Int J Oncol 24: 435-440, 2004.
33. Williams TM and Lisanti MP: Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288: C494-506, 2005.
34. Cohen AW, Hnasko R, Schubert W and Lisanti MP: Role of caveolae and caveolins in health and disease. Physiol Rev 84: 1341-1379, 2004. (Pubitemid 39287953)
35. Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC and Stanford JL: Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 70: 1020-1035, 2010.
36. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD and Thompson TC: Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61: 3882-3885, 2001. (Pubitemid 32720945)
37. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T and Brothman AR: Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46: 249-256, 2001. (Pubitemid 32142772)
38. Pflug BR, Reiter RE and Nelson JB: Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 40: 269-273, 1999. (Pubitemid 29398054)